PharmaEngine (ROCO:4162) Additional Paid-In Capital : NT$1,616 Mil(As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is PharmaEngine Additional Paid-In Capital?

PharmaEngine's quarterly additional paid-in capital declined from Sep. 2024 (NT$1,616 Mil) to Dec. 2024 (NT$1,616 Mil) but then stayed the same from Dec. 2024 (NT$1,616 Mil) to Mar. 2025 (NT$1,616 Mil).

PharmaEngine's annual additional paid-in capital declined from Dec. 2022 (NT$1,617 Mil) to Dec. 2023 (NT$1,616 Mil) and declined from Dec. 2023 (NT$1,616 Mil) to Dec. 2024 (NT$1,616 Mil).

PharmaEngine Additional Paid-In Capital Historical Data

The historical data trend for PharmaEngine's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaEngine Additional Paid-In Capital Chart

PharmaEngine Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,619.84

1,619.93

1,616.73

1,616.01

1,615.94

PharmaEngine Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,616.01	1,616.01	1,616.01	1,615.94	1,615.94

PharmaEngine Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

PharmaEngine Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of PharmaEngine's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaEngine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaEngine Inc (ROCO:4162) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104

Website

https://www.pharmaengine.com

PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.

PharmaEngine Headlines

No Headlines